Copyright
©The Author(s) 2019.
World J Gastrointest Oncol. Oct 15, 2019; 11(10): 866-876
Published online Oct 15, 2019. doi: 10.4251/wjgo.v11.i10.866
Published online Oct 15, 2019. doi: 10.4251/wjgo.v11.i10.866
Table 4 Clinical risk factors of a primary or secondary outcome for all anticoagulation therapies
| Clinical risk factor | Odds ratio | 95%CI | Significance level |
| Active treatment | 5.1 | 1.3-19.3 | P = 0.0167 |
| Khorana score high | 5.5 | 1.7-17.1 | P = 0.0033 |
| Active smoker | 6.7 | 2.1-21.0 | P = 0.0012 |
| Pancreatic cancer | 6.8 | 1.9-23.2 | P = 0.0023 |
| Stage IV | 9.9 | 1.2-79.1 | P = 0.0306 |
| Death after an event | 17.4 | 4.7-63.4 | P < 0.0001 |
- Citation: Recio-Boiles A, Veeravelli S, Vondrak J, Babiker HM, Scott AJ, Shroff RT, Patel H, Elquza E, McBride A. Evaluation of the safety and effectiveness of direct oral anticoagulants and low molecular weight heparin in gastrointestinal cancer-associated venous thromboembolism. World J Gastrointest Oncol 2019; 11(10): 866-876
- URL: https://www.wjgnet.com/1948-5204/full/v11/i10/866.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v11.i10.866